Relyvrio (sodium phenylbutyrate/taurursodiol) 3g/1g
Relyvrio (sodium phenylbutyrate and taurursodiol) can be taken orally by combining one packet in 8 ounces of room temperature water. It can also be administered through a feeding tube. Relyvrio can be taken alone and in combination with existing ALS treatments. Relyvrio was approved by the FDA in July 2022.
| Brand Name | Relyvrio |
| Manufacturer | Amylyx Pharmaceuticals |
| Dose | 3g/1g |
| Packaging Type | Vial |
| Packaging Size | 7 single dose |
| Brand | Relyvrio |
| Composition | 3g of sodium phenylbutyrate and 1g of taurursodiol |
| Injectable Form | Suspension |
| Medicine Type | Allopathic |
Product Description
RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults. The recommended initial dosage of RELYVRIO for oral suspension is 1 packet (3 g sodium phenylbutyrate and 1 g taurursodiol) daily for the first 3 weeks.
Reviews
There are no reviews yet.